Everolimus in Anaplastic Thyroid Cancer: A Case Series

Everolimus in Anaplastic Thyroid Cancer: A Case Series

Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol.Methods: Patients with confirmed...

Full description

Bibliographic Details
Main Authors: Ethan J. Harris, Glenn J. Hanna, Nicole Chau, Guilherme Rabinowits, Robert Haddad, Danielle N. Margalit, Jonathan Schoenfeld, Roy B. Tishler, Justine A. Barletta, Matthew Nehs, Pasi Janne, Julian Huang, Phillip Groden, Alec Kacew, Jochen Lorch
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Oncology
Subjects:
anaplastic thyroid cancer (ATC)
precision medicine
mTOR inhibition in head and neck cancer
exceptional responder
PI3K mTOR
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00106/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00106/full

Similar Items